Jean-Bernard Deloye, Head of Market Access, Becomes Part of Leem’s Board

New York, N.Y (USA) and Paris (France), May 29, 2019 – Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging Companion Diagnostics (CDx) for targeted therapies in oncology, today announced that Jean-Bernard Deloye, Head of Market Access, becomes part of Leem’s board. Leem is the French industry association which represents drug companies operating in France.

On May 28, 2019, Leem’s board has co-opted five new members, including Jean-Bernard Deloye, Head of Market Access at Zionexa. He becomes part of the subgroup “small French laboratories” of the board. On a national level, Leem acts as a champion and advocate for the pharmaceutical industry. In this capacity, it participates in numerous official, ministerial and inter-ministerial committees. Leem is a member of the French Federation of Healthcare Industries (FEFIS) and of the French Enterprise Movement (MEDEF). At international level, Leem is a member of the European Federation of Pharmaceutical Associations and Industries (EFPIA) and of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

« This new mission is a privilege. Leem’s board ensures the profession representativeness and set strategic orientations, while promoting our sector, mostly in France but also internationally.” – Jean-Bernard Deloye, Head of Market Access

Peter Webner, CEO US